Relative advantages and disadvantages of factor XII or factor XI as targets for new anticoagulants
| . | Factor XII . | Factor XI . |
|---|---|---|
| Epidemiological data | Weak | Stronger |
| Risk for bleeding | None | Low |
| Level of evidence for role in thrombosis | Preclinical | Phase 2 |
| Potential for bypassing inhibition | Thrombin-mediated activation of factor XI could bypass factor XII inhibition | None |
| Potential for off target effects | May modulate inflammation by inhibiting bradykinin generation | Unlikely |
| . | Factor XII . | Factor XI . |
|---|---|---|
| Epidemiological data | Weak | Stronger |
| Risk for bleeding | None | Low |
| Level of evidence for role in thrombosis | Preclinical | Phase 2 |
| Potential for bypassing inhibition | Thrombin-mediated activation of factor XI could bypass factor XII inhibition | None |
| Potential for off target effects | May modulate inflammation by inhibiting bradykinin generation | Unlikely |